The gastrointestinal stromal tumor (GIST) pipeline will rise with various collaborations and R&D investments. Hereditary risk and genetic factors play an important role in the development of gastrointestinal stromal tumor. Increasing family history of the disease and genetic factors associated with gastrointestinal stromal tumor and low penetration in the market are contributing towards the development of the pipeline. Additionally, increasing awareness regarding various health issues among people is another major factor fueling the pipeline growth for gastrointestinal stromal tumor. According to American Cancer Society, every year around 4,000 to 5,000 people suffer from gastrointestinal stromal tumor in the U.S. Gastrointestinal stromal tumors occur mostly in older adults with age more than 50 years. It affects women and men equally.
Gastrointestinal stromal tumorsis rare form of tumor which is found in gastrointestinal tract or digestive tract. It mostly occurs on the walls of stomach, varying from benign to malignant. The symptoms of gastrointestinal stromal tumors include pain or discomfort in the stomach, blood in vomit or stools, fatigue, sickness and anaemia. But in the early stages of the disease symptoms does not occur resulting in late diagnosis of the tumor. The diagnosis of Gastrointestinal stromal tumors is done by conducting endoscopy, magnetic resonance imaging (MRI) and computed tomography (CT) scan. The treatment of gastrointestinal stromal tumors include surgery and biological therapies. Surgery is the most common treatment for gastrointestinal stromal tumors and it is chosen by analysing the location of the tumor and the size of the tumor. Biological therapies include treatment with drugs including Imatinib (Glivec), Sunitinib (Sutent) and Regorafenib (Stivarga).
Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/gastrointestinal-stromal-tumor-pipeline-analysis/toc-sample
Some of the companies having a pipeline of gastrointestinal stromal tumors therapeutics include Chipscreen Biosciences Ltd., GlaxoSmithKline plc, Pfizer, Boston Biomedical, Inc., Bayer AG, Immunicum AB, Plexxikon, Inc., Blueprint Medicines Corporation, Array BioPharma Inc., ArQule, Inc., Arog Pharmaceuticals, Inc., Merck Sharp & Dohme Corp., Deciphera Pharmaceuticals LLC.
About P&S Market Research
P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.
As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY – 10016
Toll-free: +1-888-778-7886 (USA/Canada)